# Siddhartha Kadia

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/siddhartha-kadia
Canonical HTML page: https://getbiobrief.com/entity/siddhartha-kadia

## Recent coverage (1 stories)

### Biopharma Development Push: Mesa Labs Targets 290bps Margin Gains in Q1
2026-08-11 01:58:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Mesa Laboratories' new CEO is prioritizing product development in Biopharmaceutical Development, a segment poised to benefit from growth in biologic and cell/gene therapy manufacturing. The company's Q1 adjusted operating margin hit 25.6%, providing investment capacity.
Full story: https://getbiobrief.com/story/bio-mesa-labs-q1-2027-biopharma-development

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.